David Sinclair· PhD
Treatment of 18 month old mice with a cancer drug being developed (mouse-Ganitumab/mAb IGF1-R), extended female lifespan ~10%.
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
Treatment of 18 month old mice with a cancer drug being developed (mouse-Ganitumab/mAb IGF1-R), extended female lifespan ~10%.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
we gave it to 22 months old animals that are 70 75 years of age equivalent we increase their health spend dramatically and we increase their lifespan by 10% it's an old age
they had compressed morbidity as we had a car do you know they had the cardiovascular protection they have cognitive advantage functional advantage there's a whole thing
interestingly a paper published somewhat recently this was a near Barzilai and actually Pedro Beltran whom I work with now with an antibody that antagonizes the idea yeah it extends life but there's a sex difference so it only benefits a female's
there's one study that that that i think it used a monoclonal antibody to the igf-1 receptor in mice this is from near bars and hosey cohen yeah where they treated mice with this antibody lately and they got you know a reasonably sized lifespan extension i think it was i don't know 14 15 percent median lifespan